Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Eiger Biopharmaceuticals Inc News

    2,15 $ -3,15% -0,07 $
    In : 2,0122 € | 17.04.24 21:46:31 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EKZU
    ISIN: US28249U2042
    US-Symbol: EIGRQ
    Typ: Aktie

    Eiger Biopharmaceuticals Inc News

    05.03.24 - PR Newswire
    Thinking about buying stock in Intuitive Machines, Lyell Immunopharma, Hallador Energy, Eiger Biopharmaceuticals, or WEC Energy Group?
    Thinking about buying stock in Intuitive Machines, Lyell Immunopharma, Hallador Energy, Eiger Biopharmaceuticals, or WEC Energy Group? PR Newswire
    18.01.24 - PR Newswire
    Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
    Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-​Deficient Progeroid Laminopathies in Japan PR ...
    04.01.24 - PR Newswire
    Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
    Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split PR Newswire
    09.11.23 - PR Newswire
    Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
    Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire
    12.09.23 - PR Newswire
    Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
    Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta PR Newswire
    05.09.23 - PR Newswire
    Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
    Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire
    14.08.23 - PR Newswire
    Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
    Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire
    29.06.23 - PR Newswire
    Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
    Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO PR Newswire
    28.06.23 - PR Newswire
    Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
    Eiger BioPharmaceuticals to Host Business Update Call Tomorrow PR Newswire
    03.05.23 - PR Newswire
    Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
    Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) PR Newswire
    13.04.23 - PR Newswire
    Thinking about buying stock in Bit Digital, Cipher Mining, Eiger Biopharmaceuticals, Eos Energy, or Bitfarms?
    Thinking about buying stock in Bit Digital, Cipher Mining, Eiger Biopharmaceuticals, Eos Energy, or Bitfarms? PR Newswire
    13.04.23 - PR Newswire
    Eiger BioPharmaceuticals Strengthens Management Team with New Appointments
    Eiger BioPharmaceuticals Strengthens Management Team with New Appointments PR Newswire
    16.03.23 - PR Newswire
    Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
    Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update PR Newswire
    08.02.23 - PR Newswire
    New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
    New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 PR Newswire
    09.01.23 - PR Newswire
    FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
    FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm PR Newswire
    09.01.23 - PR Newswire
    CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023
    CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023 PR Newswire
    06.01.23 - PR Newswire
    EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023
    EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 PR Newswire
    05.01.23 - PR Newswire
    EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
    EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
    05.01.23 - PR Newswire
    EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)
    EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff ...
    04.01.23 - PR Newswire
    SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR)
    SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - ...

    Newssuche

    Videos

    newspaper
    16.04.24 -9,38%
    Technical Trading: Natural Gas Long Chance
    Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »